Clinical Trials

About Lundbeck’s Clinical Trials

Lundbeck’s purpose is to restore brain health and we are grateful to the patients, healthy volunteers, families, and clinics that participate in our clinical trials. Each individual’s participation contributes to our understanding of disease and has the potential to benefit patients around the world.

About Clinical Trials

Clinical trials are essential to determine whether new drugs are safe and effective when used to treat people. 

Carefully conducted clinical trials are performed in patients and human volunteers to provide answers to questions such as:

 

  • Does a treatment work?
  • Does it work better than other treatments?
  • Does it have side effects?

Deciding to participate in a clinical trial requires careful consideration. In most cases, the therapies investigated in clinical trials are not yet approved by regulatory agencies and the benefits and risks of taking the treatment are not completely known. However, regulatory agencies and ethics committees have approved the conduct of the clinical trial. By volunteering for a clinical trial, you are helping the medical community determine whether new treatments are safe and effective.

Disclosure of Clinical Trial Information

Lundbeck registers clinical trial protocols and discloses the results of clinical trials, regardless of outcome, in a publicly accessible clinical trial registry, ClinicalTrials.gov. Non-interventional studies may also be disclosed if, for example, they are considered to provide important safety data. Clinical trial protocols and results information submitted by Lundbeck to the EudraCT database is made publicly available by the European Medicines Agency (EMA) via its clinical trial registry.

 

Lundbeck provides open access to clinical trial result summaries (synopses) from Lundbeck-sponsored phase II-IV trials completed after January 1, 2014, following market authorization in US or EU. Find the list of synopses here

 

Clinical trial reports will be accessible on the EMA’s page for clinical trial data in accordance with EMA POLICY/0070. Clinical trial information will also be accessible on Health Canada's homepage in accordance with Health Canada's guidance Public Release of Clinical Information. 


Lundbeck will seek to ensure that disclosure of clinical trial information follows the IFPMA, EFPIA, JPMA, and PhRMA joint position paper “Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases”, the Declaration of Helsinki, and other relevant clinical trial disclosure requirements.


Lundbeck respects the privacy of the relationship between patients and healthcare professionals and is committed to ensuring that the process of scientific publication and clinical trial data sharing do not breach patient confidentiality.

Clinical Trial Diversity

At Lundbeck, we strive to improve the quality of life of all people living with brain diseases. Building an inclusive clinical trials infrastructure, one that reflects the full diversity of the intended treatment population, is an important step toward combatting health inequities and racial disparities in brain health.

More from lundbeck

Pipeline

Discover our projects and compounds in development. 

Publications

Our policy for scientific publications and responsible clinical data sharing.

Corporate News

All the Latest on Lundbeck.